Protocol Ledger

NCT06534060 · Phase II · RECRUITING

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Interventional Phase II clinical trial protocol NCT06534060 sponsored by March Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-15 Enrollment: 46 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06534060
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)46 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06534060
Protocol FieldVerified Registry Value
NCT IdentifierNCT06534060
Consolidated Lead SponsorMarch Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment46 participants (ESTIMATED)
Registered Start Date2025-02-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06534060
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
University of IowaIowa City, IAOpen Hospital Dossier ->
Massachusetts General HospitalBoston, MAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI